Jeffrey J. Owens
Jeffrey J. Owens's purchase track record
Jeffrey J. Owens has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2022 | ROG | $101K | +44.3% | +60.1% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Transaction History
| INDI | ▲ Buy | Option Exercise | 2,641 | $0 | 9/1/2026 | View on chart |
| INDI | ▲ Buy | Option Exercise | 1,926 | $0 | 6/1/2026 | View on chart |
| INDI | ▲ Buy | Option Exercise | 59,932 | $0 | 5/28/2026 | View on chart |
| ROG | ▲ Buy | Grant | 1,427 | $0 | 5/6/2026 | View on chart |
| INDI | ▲ Buy | Option Exercise | 2,562 | $0 | 3/1/2026 | View on chart |
| INDI | ▲ Buy | Option Exercise | 2,694 | $0 | 12/1/2025 | View on chart |
| INDI | ▲ Buy | Option Exercise | 2,070 | $0 | 9/1/2025 | View on chart |
| INDI | ▲ Buy | Option Exercise | 23,681 | $0 | 6/4/2025 | View on chart |
| INDI | ▲ Buy | Option Exercise | 3,538 | $0 | 6/1/2025 | View on chart |
| ROG | ▲ Buy | Grant | 2,760 | $0 | 5/5/2025 | View on chart |
| INDI | ▲ Buy | Option Exercise | 2,260 | $0 | 9/1/2024 | View on chart |
| INDI | ▲ Buy | Option Exercise | 18,919 | $0 | 6/13/2024 | View on chart |
| INDI | ▲ Buy | Option Exercise | 25,000 | $0 | 6/10/2024 | View on chart |
| INDI | ▲ Buy | Option Exercise | 1,406 | $0 | 6/1/2024 | View on chart |
| ROG | ▲ Buy | Grant | 1,500 | $0 | 5/2/2024 | View on chart |
| INDI | ▲ Buy | Option Exercise | 1,367 | $0 | 3/1/2024 | View on chart |
| INDI | ▲ Buy | Option Exercise | 1,254 | $0 | 12/1/2023 | View on chart |
| INDI | ▲ Buy | Option Exercise | 1,357 | $0 | 9/1/2023 | View on chart |
| INDI | ▲ Buy | Option Exercise | 26,965 | — | 6/22/2023 | View on chart |
| INDI | ▲ Buy | Option Exercise | 25,000 | — | 6/10/2023 | View on chart |
| ROG | ▲ Buy | Grant | 950 | $0 | 5/4/2023 | View on chart |
| ROG | ▲ Buy | Open Market | 1,000 | $101K | 11/22/2022 | View on chart |
| INDI | ▲ Buy | Option Exercise | 25,000 | — | 6/10/2022 | View on chart |
| ROG | ▲ Buy | Grant | 600 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Indie Semiconductor Sets Q3 2026 Earnings Date Amid Debt Concerns
Indie Semiconductor has announced the date for its third-quarter 2026 earnings release and conference call. Recent coverage highlights concerns that the sale of its Wuxi facility may not fully resolve the company's debt issues. The stock is currently trading near its 52-week low, reflecting ongoing market scrutiny of its financial position.
Indie Semiconductor Sets Q3 2026 Earnings Date Amid Debt Concerns. Indie Semiconductor has announced the date for its third-quarter 2026 earnings release and conference call. Recent coverage highlights concerns that the sale of its Wuxi facility may not fully resolve the company's debt issues. The stock is currently trading near its 52-week low, reflecting ongoing market scrutiny of its financial position.